IPSEY
PINK Ipsen SA Sponsored ADR$40.93 ↑ +0.93 (+2.32%) Trading Up from the previous close of $40.00, and at the day’s high of $40.93
- YTD change
- +12.57%
- vs 20-day SMA
- -6.27%
- vs 200-day SMA
- +7.56%
Price ranges
Price & Performance
-7.62 (-15.70%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 19.9% away from all-time highs of $51.10
- IPSEY is up 13% since the beginning of the year
- IPSEY is up 24% over the past 12 months
- IPSEY is down 10% over the past 1 month
IPSEY reads n/a: price sits above one of the two key moving averages, the 12-month move is +23.3%.
- Previous minute
- +$0.00
- Last hour
- +$0.00
- Last 5 days
- -2.31%
- vs 8-day SMA
- +0.69%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Ipsen SA manufactures pharmaceutical products for oncology, neuroscience, and rare diseases. It operates through the following segments: Specialty Care. The Specialty Care segment focuses on oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and rare diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
